Modality
Degrader
MOA
CDK4/6i
Target
JAK1
Pathway
Notch
DMDSLECrohn's
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
Dec 2017
→ May 2030
Phase 1Current
NCT04180297
1,799 pts·DMD
2017-12→TBD·Terminated
NCT08101356
1,030 pts·Crohn's
2025-03→2030-05·Terminated
2,829 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-05-174.1y awayPh2 Data· Crohn's
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1/2
Termina…
P1/2
Termina…
Catalysts
Ph2 Data
2030-05-17 · 4.1y away
Crohn's
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04180297 | Phase 1/2 | DMD | Terminated | 1799 | PFS |
| NCT08101356 | Phase 1/2 | Crohn's | Terminated | 1030 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-1969 | Roche | Approved | BET | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET |